PMA Class III Landscape: 56,508 Records Show Cardiovascular Dominance

Executive Summary

The FDA Premarket Approval (PMA) pathway is the most stringent regulatory route for medical devices, reserved for Class III devices that support or sustain human life or present a potential unreasonable risk of illness or injury. Unlike the 510(k) pathway — which clears roughly 3,000 devices annually — PMA approvals are rare, with typically 20–50 original approvals per year.

Our analysis of the complete FDA PMA database — 56,508 records spanning 1960 to June 2026, from 807 unique applicants — reveals a market defined by extreme concentration. Cardiovascular devices account for 50.8% of all PMA records. The top five applicants (across their various entity names) hold 31.5% of all PMA activity. And the supplement process — post-approval modifications — generates 97.4% of all PMA records, with some devices accumulating hundreds of supplements over decades of market presence.

This article quantifies the concentration, identifies the dominant applicants and specialties, traces the lifecycle of PMA supplements, and examines the year-over-year trends in original approvals and supplements.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the FDA PMA (Premarket Approval) database (public dataset, extracted June 2026). The dataset includes 56,508 records — each representing either an original PMA approval or a PMA supplement (a post-approval modification). Records include applicant name, supplement number, product code, advisory committee/panel, trade name, generic name, decision date, supplement reason, and state.

Original PMAs are identified as records with no supplement number or a supplement number of 0. All other records are classified as supplements. Where applicant names vary across entity changes (e.g., "Boston Scientific Corp" vs. "Boston Scientific" vs. "Boston Scientific Corporation"), these are counted separately as they appear in the database — readers should be aware that the true concentration is even higher than reported when corporate families are consolidated.

Original Approvals vs. Supplements: 97.4% Are Supplements

The split between original PMA approvals and supplements is dramatic:

For every original PMA approval, there are on average 37.6 supplements over the device's lifetime. This ratio reflects the nature of Class III device regulation: the original approval is just the beginning. As manufacturers modify designs, change materials, update manufacturing processes, alter sterilization methods, and expand indications, each change that could affect safety or effectiveness requires a PMA supplement.

Advisory Committee: Cardiovascular Dominates

The FDA assigns each PMA to an advisory committee based on the device's clinical area. The distribution is heavily skewed:

Cardiovascular holds a dominant position — more than half of all PMA records and 30.5% of original PMA approvals. This reflects the inherent risk profile of cardiovascular devices (pacemakers, defibrillators, heart valves, stents, grafts), which are almost universally Class III and require PMA.

The Microbiology panel's 10.5% share of original PMAs is notable, driven by blood screening assays and infectious disease diagnostics that are classified as Class III because they screen the blood supply.

Cardiovascular Original PMAs: Who Holds Them

Among the 446 original cardiovascular PMA approvals, the concentration is remarkable:

If we consolidate the three Boston Scientific entity names (27 + 21 + 11 = 59), the company holds approximately 13.2% of all original cardiovascular PMAs — more than any other single organization. Combined Medtronic entities (35 + 13 + 8 + 7 = 63 from the full dataset) hold approximately 14.1%.

Top Applicants: A Handful of Companies Drive PMA Activity

The PMA landscape is more concentrated than any other FDA device pathway:

Cumulative concentration:

• Top 5 applicants: 17,789 records (31.5%)

• Top 10 applicants: 23,183 records (41.0%)

• Top 20 applicants: 28,964 records (51.3%)

The top 20 applicants control more than half of all PMA activity. This concentration far exceeds the 510(k) pathway, where the top 20 hold just 5.3%.

When Entity Names Are Consolidated

Because the database lists different entity names for the same corporate family, the true concentration is even higher. A conservative consolidation of Medtronic-related entities (Medtronic, Inc.; Medtronic Cardiac Rhythm Disease Management; Medtronic Neuromodulation; Medtronic Vascular; Medtronic Minimed; Medtronic Vascular, Inc.) yields approximately 11,000+ PMA records — nearly 20% of all PMA activity from a single corporate family.

Similarly, consolidating Boston Scientific entities (Boston Scientific Corp; Boston Scientific; Boston Scientific Corporation) yields approximately 6,343 records — 11.2% of total.

Original PMA Applicants (Not Supplements)

When examining only original PMA approvals (excluding supplements), the rankings shift:

The appearance of diagnostic companies (DiaSorin, Roche Molecular Systems, Abbott Laboratories) in the original PMA rankings reflects the Class III classification of blood banking and infectious disease screening assays — a category that generates original PMA applications but relatively fewer supplements compared to cardiovascular implants.

The Supplement Lifecycle: How Devices Evolve After Approval

PMA supplements are the primary mechanism through which Class III devices are modified post-approval. The volume is extraordinary:

• 1,594 unique PMA numbers have received at least one supplement

• Mean supplements per PMA: 34.5

• Median supplements per PMA: 14

• Maximum: 925 supplements for a single PMA (Medtronic Cardiac Rhythm Disease Management, P980016)

Most-Supplemented PMAs

The top 10 most-supplemented PMAs are all cardiovascular or neurostimulation devices — implantable products that undergo continuous iterative improvement over decades. A single pacemaker platform can accumulate 500+ supplements as materials, firmware, packaging, manufacturing processes, and labeling are updated over 20+ years on market.

Supplement Reasons

Manufacturing process changes are the single largest driver of supplements (55.5%), reflecting the complexity of maintaining validated manufacturing processes for Class III devices over extended market lifetimes. Design and material changes (21.0%) are the second most common, capturing the iterative innovation cycle for implantable devices.

A Harvard study analyzing cardiovascular PMA supplements found that the median PMA for cardiac implantable electronic devices (CIEDs) accumulates 50 supplements, and over one-third of supplements involve at least minor alterations to device design or materials. In the vast majority of cases, the FDA approved these changes without requiring new clinical data.

Year-Over-Year Trends

Original PMA Approvals by Year

Original PMA approvals have fluctuated within a relatively narrow range:

The peak in recent years was 2017 (46 original PMAs), while 2022 saw a trough at just 22. The 2025 figure of 40 represents the highest annual total since 2018, suggesting a possible recovery in high-risk device innovation reaching the approval stage. Annual original PMA approvals typically range from 20 to 50 — a small fraction compared to the ~3,000 510(k) clearances per year.

Total PMA Activity (Original + Supplements) by Year

Total PMA activity (originals + supplements) has grown from ~1,000 records per year in the early 2000s to over 2,000 per year since 2010. This growth is driven almost entirely by supplements — reflecting the expanding installed base of PMA-approved devices requiring ongoing modifications.

Product Code Analysis

The top PMA product codes reveal the device types that dominate Class III:

Intraocular lenses (HQL, 60 original PMAs) lead by a significant margin, reflecting the diversity of IOL designs and the ongoing innovation in ophthalmic implant technology. Coronary stents (MAF) and endovascular grafts (MIH) are also prominent — both are high-volume, clinically critical cardiovascular implants.

Geographic Concentration (US State)

PMA activity is heavily concentrated in a handful of US states, reflecting the headquarters locations of major device companies:

Minnesota (18,394 records, 32.6% of total) dominates, driven by Medtronic's headquarters and Boston Scientific's CRM operations in the state. California (15,065, 26.7%) is second. Together, these two states account for 59.2% of all PMA records — an extraordinary geographic concentration that mirrors the corporate concentration.

What This Means for Industry

Three implications stand out:

1. The PMA pathway is a closed club. With the top 20 applicants controlling 51.3% of all PMA activity, and just three corporate families (Medtronic, Boston Scientific, Abbott) likely controlling a third or more when consolidated, the Class III device space is an oligopoly. New entrants face not only the clinical and regulatory barriers of PMA, but also a competitive landscape dominated by entrenched players with decades of supplement infrastructure.

2. Supplements are the real PMA workload. For every original PMA approval, there are on average 37.6 supplements. For regulators, this means the PMA workload is overwhelmingly about managing post-approval changes rather than evaluating new devices. For manufacturers, the supplement process is a permanent operational commitment — maintaining a Class III device on the US market requires continuous regulatory resources.

3. Cardiovascular dominance shapes the entire pathway. With 50.8% of all PMA records in cardiovascular, the FDA's PMA review capacity, advisory committee expertise, and supplement management processes are heavily oriented toward cardiovascular devices. Companies in other specialties (ophthalmic, microbiology, orthopedic) operate in a different — and often less resourced — regulatory environment within the same pathway.

Data source: FDA PMA (Premarket Approval) database; analysis by MedDeviceGuide, run date 2026-06-10. Analysis sample: complete database extract, 56,508 records from 1960 through June 2026 covering 1,464 original PMA approvals and 55,044 supplements from 807 unique applicants.